Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 701 switchover study in rhGAA-exposed late-onset Pompe disease
2013-001768-48Phase 3Terminated
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Oct 2013
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reveglucosidase alfa in Pompe disease, sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Percent predicted maximal inspiratory pressure. Started Oct 2013; status: terminated.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2013-001768-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001768-48.